

FAST 15: The Status of HIV in 2021

Casey Messer, DHSc, PA-C, AAHIVS
Program Director, Ryan White
Palm Beach County
West Palm Beach, FL



Disclosure

I, Casey Messer, have no relevant financial, professional or personal relationships with commercial interests to disclose



Objectives

At the conclusion of this session, the participant will be able to:

- Discuss the current status of the HIV epidemic in the US
- Identify updated guidelines for prevention & treatment of HIV
- Evaluate clinical indications for the newest FDA-approved HIV treatment medications





HIV Epidemiology Overview

- Approximately 1.2 million people in the U.S. are living with HIV
- New infections are steady at ~38,000 per year
- 1 in 7 (14%) persons living with HIV are unaware
- More than 50 percent of new diagnoses occur in 48 counties; Washington, DC; and San Juan, Puerto Rico



HIV Epidemiology Overview

HIV disproportionately affects southern states





Source: CDC, 2020



HIV Epidemiology Overview

HIV disproportionately affects racial/ethnic minorities



Source: CDC, 2020



HIV Prevention

- Harm reduction approaches are individualistic based on risk
 - Abstinence/nonpenetrative sexual contact/mutual monogamy
 - Consistent condom use
 - Durable viral suppression (U=U)
 - Biomedical interventions
 - Pre-Exposure Prophylaxis (PrEP)
 - Post-Exposure Prophylaxis (PEP)
 - Occupational vs nonoccupational exposure



HIV PrEP

- Pre-Exposure Prophylaxis (PrEP)
 - An option for anyone who injects drugs or is not in a mutually monogamous sexual relationship with an HIV negative partner
 - Daily oral administration is the only FDA-approved dosing
 - emtricitabine/tenofovir disoproxil fumarate (F/TDF)
 - emtricitabine/tenofovir alafenamide (F/TAF)
 - HIV Ag/Ab, Hep B surface ab/ag, Creatinine at baseline
 - Repeat Creatinine at 3 months after initiation, then annually
 - HIV Ag/Ab every 3 months (also other STIs, HCG)
 - PrEP Consultation Service
 - 855-448-7737



HIV PEP

- Occupational Post-Exposure Prophylaxis
 - Follow your employers guidelines and protocols
- Nonoccupational Post-Exposure Prophylaxis (nPEP)
 - Evaluate <72 hours after potential exposure
 - HIV testing, combination Ag/Ab preferred, or rapid antibody test
 - Emtricitabine/tenofovir disoproxil fumarate (200mg/300mg) once daily
 - plus*
 - dolutegravir 50mg daily OR raltegravir 400mg twice daily**
 - 28-day course, with re-testing following completion
 - PEP Consultation Service
 - 1-888-448-4911



HIV Testing

- The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. (CDC 13-64)
- Ag/Ab combination (4th generation)
- More frequent HIV screening should be provided to patients living in high HIV incidence areas and among populations disproportionately burdened:
 - Southern US
 - Black/African Americans
 - Gay/bisexual/same-gender-loving Men



HIV Treatment

- DHHS Guidelines on use of Antiretroviral Agents (December 2019)
 - Antiretroviral Therapy (ART) should be started immediately or as soon as possible after diagnosis
 - Dolutegravir may be used as alternative regimen for persons of childbearing age who are not using contraception, recommended option for individuals using effective contraception
 - Increase in age-related comorbidities for long-term survivors
 - Recommended Initial Regimens
 - Multiple triple therapy combination single tablet regimens
 - dolutegravir/lamivudine
 - bictegravir/tenofovir alafenamide/emtricitabine (before drug resistance testing)



HIV Treatment

- Newest FDA-approved HIV treatment medication
 - cabotegravir plus rilpivirine (Cabenuva) long-acting injectable
 - Maintenance “switch” therapy for virologically suppressed adults
 - No history of treatment failure
 - No known or suspected resistance to cabotegravir or rilpivirine
 - Dosed once monthly as two injections
 - Lead-in of oral cabotegravir (30mg) and rilpivirine (25mg) for 30 days prior to injections
 - Initial injections include 600mg cabotegravir + 900mg rilpivirine
 - Continuation injection dose of 400mg cabotegravir + 600mg rilpivirine
 - 7 day grace period of injection due date, oral medications should be restarted



Frequently Asked Questions

When will there be an HIV vaccine?



Frequently Asked Questions

What's the latest on long-acting HIV medications?



The State of HIV in 2021 Summary

- In the US, rates of HIV have plateaued over the last 8 year
 - Disparities exist among racial/ethnic minorities and southern states
- HIV Prevention
 - PrEP & PEP
 - PrEP Consultation Service 855-448-7737
 - PEP Consultation Service 1-888-448-4911
- HIV Testing
 - Routine, opt-out testing adolescents and adults aged 15 to 65 years



The State of HIV in 2021 Summary

- HIV Treatment
 - Test & Treat
 - Multiple single-tablet regimens as first line therapy
- New FDA-approved long-acting injectable
 - cabotegravir plus rilpivirine (Cabenuva)
 - Once monthly injections
 - Switch therapy, not for treatment naïve
- Future Forecasts
 - HIV vaccine is still elusive
 - New medication classes, injectable, implants, MPT's



References

- Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep.* 2006;55(RR-14):1-17.
- Casazza JP et al. *Durable HIV-1 antibody production in humans after AAV8-mediated gene transfer.* Conference on Retroviruses and Opportunistic Infections, abstract 41LB, March 2020.
- Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2014-2018. HIV Surveillance Supplemental Report 2020;25(No. 1). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2020.
- Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf>. Published March 2018.
- Crotty S. *Engineering vaccine immunity.* Conference on Retroviruses and Opportunistic Infections, plenary presentation 112, March 2020.
- Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV epidemic: a plan for the United States. *JAMA.* 2019;321(9):844-845.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at <http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf>
- US Preventive Services Task Force. Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2019;321(23):2326-2336. doi:10.1001/jama.2019.6587
- Wilson PA, Nanin J, Amesty S, Wallace S, Cherenack EM, Fullilove R. Using syndemic theory to understand vulnerability to HIV infection among Black and Latino men in New York City. *J Urban Health.* 2014;91(5):983-998. doi:10.1007/s11524-014-9895-2



Questions and Answers

Thank you!

Casey Messer

cmesser@pbcgov.org

561-355-4730

